Company news
Kintor Pharmaceutical Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 2, 2026
Update on measures and actions taken in resolving the disclaimer of opinion in the annual report for the year ended 31 December 2025
October 30, 2026
Voluntary announcement - receipt of notice of grant of invention patent for KT-939
October 21, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Interim report 2026
September 29, 2026
Resignation of chief financial officer, joint company secretary and process agent, appointment of chief financial officer and appointment of process agent
September 21, 2026
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
July 25, 2025
Kintor Pharmaceutical: Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine
October 27, 2023
Kintor Pharmaceutical: Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
October 11, 2023
Kintor Pharmaceutical: Pharma Announces 2023 Interim Results and Recent Business Highlights
August 28, 2023
Kintor Pharmaceutical: Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
August 22, 2023
Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
July 20, 2023
Kintor Pharmaceutical: Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
May 11, 2023
Kintor Pharmaceutical: Pharma Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematologic Malignancies in China
May 8, 2023
Kintor Pharmaceutical: Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US
April 18, 2023
Kintor Pharmaceutical: Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
April 14, 2023
Kintor Pharmaceutical: Pharma Announces 2022 Annual Results and Recent Business Progress
March 30, 2023
Kintor Pharmaceutical: Pharma Announces Preclinical Data of GT1708F at AACR 2023
March 16, 2023
Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use
November 23, 2022
Kintor Pharmaceutical: Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
November 9, 2022
Kintor Pharmaceutical: Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
October 27, 2022
Kintor Pharmaceutical: Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China
October 16, 2022
Phase Ib Data of GT0918 for AR+ mBC Published in EJC
September 29, 2022
Kintor Pharmaceutical: Pharma Announces 2022 Interim Results and Recent Business Highlights
August 29, 2022
Kintor Pharmaceutical: Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
August 3, 2022
Kintor Pharma Included in MSCI China Index
May 15, 2022
Kintor Pharmaceutical: Pharma Announces Two Upcoming Poster Presentations at AACR 2022
April 3, 2022